MarketCap
Facebook
X
Telegram
Aytu BioScience Balance Sheet 2025-2005 | AYTU
Brief balance sheet overview of Aytu BioScience
The comparison uses five available annual reports from the 2019–2023 interval.
Assets rose from $34.7 million to $136.5 million, a gain of +293%, while CAGR was about 40.8%. The balance sheet expanded rapidly.
Liability growth of +251.4% trailed asset growth of +293%. The funding structure became more resilient.
Equity finances 28.8% of the balance sheet, compared with 20.4% at the start. The cushion remains adequate.
Net debt moved below zero to -$7 million, reflecting surplus cash over debt.
Cash represents 16.8% of assets versus 31.8% initially, showing how the immediate liquidity reserve changed.
The balance sheet includes a negative accumulated result of -$304.1 million. It should be assessed alongside historical profits and capital distributions.
Overall assessment
Aytu BioScience has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-19.9 M | -8.42 M | -7.01 M | -3.13 M | -48.5 M | -45.6 M | -11 M | -7.01 M | -802 K | -8.05 M | -7.35 M | -2.64 M | 97.6 K | 67.9 K | 48.3 K | - | - | - | - | - | - |
Long Term Debt |
10.9 M | 10.9 M | 14.7 M | 15 M | 180 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
137 K | 712 K | 1.26 M | 1.23 M | 940 K | 300 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
42.1 M | 28.2 M | 28.1 M | - | - | 29.5 M | 22.3 M | 4.24 M | 7.39 M | 4.15 M | 1.13 M | 554 K | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
63.1 M | 62.2 M | 69 M | 64.4 M | 109 M | 28.3 M | 5.37 M | 3.39 M | 3.61 M | 10.1 M | 1.48 M | - | 121 K | 82.4 K | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 97.1 M | 93.3 M | 128 M | 57.8 M | 27.6 M | 7.64 M | 11 M | 14.3 M | 2.61 M | 6.65 M | 121 K | 82.4 K | 58.4 K | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 339 K | - | - | - | - | 85.7 K | 85.7 K | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-334 M | -320 M | -304 M | -287 M | -178 M | -120 M | -106 M | -79.3 M | -69.1 M | -46.6 M | -18.4 M | -10.7 M | -569 K | -500 | -500 | - | - | - | - | - | - |
Total Assets |
124 M | 118 M | 136 M | 138 M | 266 M | 153 M | 34.7 M | 21.1 M | 15 M | 24.3 M | 18.2 M | 12 M | 9.67 K | 12.6 K | 22.8 K | - | - | - | - | - | - |
Cash and Cash Equivalents |
31 M | 20 M | 23 M | 19.4 M | 49.6 M | 48.1 M | 11 M | 7.01 M | 802 K | 8.05 M | 7.35 M | 2.64 M | 1.86 K | 109 | 3.99 K | 1.54 K | - | - | - | - | 100 |
Book Value |
124 M | 118 M | 39.4 M | 44.3 M | 138 M | 95 M | 7.09 M | 13.4 M | 4 M | 10.1 M | 15.6 M | 5.37 M | -111 K | -69.7 K | -35.6 K | - | - | - | - | - | - |
Total Shareholders Equity |
19 M | 27.7 M | 39.4 M | 44.3 M | 138 M | 95 M | 7.09 M | 13.4 M | 4 M | 10.1 M | 15.6 M | 5.37 M | -111 K | -69.7 K | -35.6 K | -55.6 K | -13.6 K | 26 K | 18.8 K | 57.9 K | 20.4 K |
All numbers in USD currency
Quarterly Balance Sheet Aytu BioScience
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
9.55 M | 10 M | 10.4 M | 10 M | 10.4 M | 10.9 M | 9.54 M | 9.98 M | 10.4 M | 10.9 M | - | 15 M | 15 M | 14.7 M | 15 M | 15 M | 15 M | 15 M | 15 M | 129 K | 154 K | 180 K | 180 K | 211 K | 237 K | - | 8.16 M | 23.4 M | 314 K | - | 5.13 M | 5.04 M | - | 5.04 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
16.6 M | 42.2 M | 35.8 M | 42.2 M | 35.8 M | 42.1 M | 18.6 M | 21.4 M | 24.8 M | 28.2 M | 14.4 M | 34.2 M | - | 28.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | 101 M | 97.1 M | 106 M | 95.6 M | 96.1 M | 93.3 M | 108 M | 118 M | 116 M | 128 M | 128 M | 54 M | 50.2 M | 58.3 M | 57.8 M | 57.4 M | 28.7 M | 27.6 M | 27.6 M | 22.5 M | 7.85 M | 22.5 M | 7.64 M | 15.8 M | 14.9 M | 11 M | 11 M | 11.1 M | 13 M | 14.3 M | 14.3 M | 9.15 M | 7.95 M | 2.57 M | 2.61 M | - | 6.66 M | 6.65 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100 K | 100 K | 400 K | 100 K | 200 K | 200 K | 200 K | 200 K | 476 K | 233 K | 339 K | 339 K | - | - | - | - | 14 K | - | 14 K | - | - | - | - | - | - | - | - | 85.7 K | 85.7 K | 85.7 K | 85.7 K | 85.7 K | - | 85.7 K | 85.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-348 M | -342 M | -332 M | -342 M | -332 M | -334 M | -314 M | -318 M | -318 M | -320 M | -315 M | -312 M | -312 M | -304 M | -302 M | -294 M | -291 M | -287 M | -271 M | -218 M | -206 M | -178 M | -178 M | -134 M | -124 M | -120 M | -120 M | -112 M | -111 M | -106 M | -106 M | -87.4 M | -82.7 M | -87.4 M | -79.3 M | -77 M | -73.3 M | -69.1 M | -69.1 M | -57.1 M | -52.3 M | -46.6 M | -46.6 M | -24 M | -20.7 M | -18.4 M | -18.4 M | -646 K | -630 K | -10.7 M | -630 K | -500 | -500 | -500 | -500 | -500 | -500 | -500 | -500 | -500 | -500 | -500 | -500 |
Total Assets |
112 M | 122 M | 125 M | 122 M | 125 M | 124 M | 124 M | 116 M | 116 M | 118 M | 129 M | 131 M | 133 M | 136 M | 147 M | 141 M | 150 M | 138 M | 169 M | 224 M | 228 M | 266 M | 266 M | 167 M | 141 M | 153 M | 153 M | 74.5 M | 31 M | 34.7 M | 34.7 M | 42.4 M | 18 M | 42.4 M | 21.1 M | 18.9 M | 21.2 M | 15 M | 15 M | 21.5 M | 15 M | 21.5 M | 20.2 M | 24.4 M | 21.4 M | 18.2 M | 18.2 M | 11.2 K | 5.51 K | 12 M | 5.51 K | 7.16 K | 9.67 K | 9.67 K | 9.67 K | 11.9 K | 12.6 K | 12.6 K | 12.6 K | 18.8 K | 22.8 K | 22.8 K | 22.8 K |
Cash and Cash Equivalents |
26.7 M | 30 M | 32.6 M | 30 M | 32.6 M | 31 M | 18.2 M | 20.4 M | 20.1 M | 20 M | 19.8 M | 19.5 M | 20 M | 23 M | 19.2 M | 19.5 M | 23.8 M | 19.4 M | 27.6 M | 35.3 M | 40.3 M | 49.9 M | 49.6 M | 62 M | 37.9 M | 62 M | 37.9 M | 5.26 M | 7.01 M | 11 M | 11 M | 17.8 M | 3.96 M | 17.8 M | 7.01 M | 3.91 M | 7.02 M | 802 K | 802 K | 5.23 M | 2.75 M | 8.05 M | 8.05 M | 11 M | 10.1 M | 11 M | 10.1 M | 161 K | 1.05 M | 2.64 M | 4.12 M | 445 | 1.86 K | 2.91 M | 445 | 701 | 109 | 109 | 701 | 1.72 K | 3.99 K | 3.99 K | 1.72 K |
Book Value |
112 M | 122 M | 125 M | - | - | - | - | - | - | - | - | - | 32.2 M | 39.4 M | 40.9 M | 45.8 M | 53.9 M | 44.3 M | 61.1 M | 106 M | 112 M | 138 M | 138 M | 113 M | 91.1 M | 95 M | 95 M | 17.1 M | 2.32 M | 7.09 M | 7.09 M | 19.9 M | 10.1 M | 19.9 M | 13.4 M | 3.03 M | 6.35 M | 4 M | 4 M | 10.4 M | 1.99 M | 7.25 M | 5.94 M | 15.3 M | 13.4 M | 15.6 M | 15.6 M | 11.2 K | -6.65 M | 5.37 M | 5.51 K | 7.16 K | 9.67 K | 9.67 K | 9.67 K | 11.9 K | 12.6 K | 12.6 K | 12.6 K | 18.8 K | 22.8 K | 22.8 K | 22.8 K |
Total Shareholders Equity |
35.1 M | 14.2 M | 23.2 M | 14.2 M | 23.2 M | 19 M | 34.9 M | 30.8 M | 29.8 M | 27.7 M | 30.8 M | 32.9 M | 32.2 M | 39.4 M | 40.9 M | 45.8 M | 48.3 M | 44.3 M | 57.7 M | 106 M | 112 M | 138 M | 138 M | 113 M | 113 M | 113 M | 91.1 M | 17.1 M | 17.1 M | 17.1 M | 2.32 M | 19.9 M | 19.9 M | 19.9 M | 10.1 M | 3.03 M | 6.35 M | 3.03 M | 6.35 M | 10.4 M | 7.19 M | 10.1 M | 10.1 M | 15.3 M | 13.4 M | 15.6 M | 15.6 M | -44.1 K | -45 K | 5.37 M | -45 K | -126 K | -111 K | -111 K | -111 K | -82.2 K | -69.7 K | -69.7 K | -69.7 K | -47.6 K | -35.6 K | -35.6 K | -35.6 K |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Aytu BioScience, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
China
France
Singapore
Britain
Germany
Israel
Russia
Belgium
